Monitor the company's ability to secure additional financing by Q3 2026, as its current cash runway extends only to April 2027. Track progress on the LaunXP receivable collection and the outcome of the Medpace litigation, both of which could significantly impact liquidity. The stock is likely to remain under pressure until the company demonstrates a viable path to resolving its going concern issues.
Price Chart
Executive Summary
Apollomics reported a net loss of $10.9 million for 2025, with only $3.3 million in cash as of year-end, insufficient to meet obligations through April 2027. The company secured a $2.0 million bridge loan from its CEO and is pursuing additional capital. Its lead drug, vebreltinib, faces development delays and patent risks, while a $5.0 million settlement and ongoing litigation with Medpace strain finances. Despite a recent equity raise, substantial doubt remains about its ability to continue as a going concern.
Key Facts
- Net loss of $10.9 million for the year ended December 31, 2025
- Cash and cash equivalents of $3.3 million as of December 31, 2025
- Management has determined there is substantial doubt about the company's ability to continue as a going concern
- Received a $2.0 million unsecured convertible bridge loan from CEO Hung-Wen (Howard) Chen on March 30, 2026
- Recorded a $10.0 million impairment loss for the uproleselan program due to failed clinical trials
- Entered into a $5.0 million settlement agreement with minority investors (TWVC Entities)
- Actively litigating with Medpace, Inc. with potential damages exceeding $2.0 million
- LaunXP International has only paid $6.2 million of a $10.0 million upfront payment, with $2.3 million recorded as receivable
- The U.S. NDA filing for vebreltinib has been indefinitely deferred due to insufficient clinical data
Financial Impact
The company faces a $7.6 million funding gap (current cash of $3.3M + $2.3M receivable + $2.0M bridge loan) to meet obligations through April 2027, with ongoing litigation exposure of $5.0M+ and potential future capital raises likely to be dilutive.
Risk Factors
- Insufficient cash to meet obligations, raising substantial doubt about going concern status
- Ongoing litigation with Medpace and a $5.0 million settlement that could severely impact cash flow
- Failure of key drug programs (uproleselan) and delays in lead candidate (vebreltinib) development
- Dependence on a single related-party bridge loan and uncertain future financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 11 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001193125-26-177357 |
| Document: aplm-ex2_1.htm | 0001193125-26-177357 |
| Document: aplm-ex12_2.htm | 0001193125-26-177357 |
| Document: aplm-ex12_1.htm | 0001193125-26-177357 |
| Document: aplm-ex15_2.htm | 0001193125-26-177357 |
| Document: aplm-ex13_1.htm | 0001193125-26-177357 |
| Document: aplm-ex13_2.htm | 0001193125-26-177357 |
| Document: aplm-ex15_1.htm | 0001193125-26-177357 |
| Document: 0001193125-26-177357-index-headers.html | 0001193125-26-177357 |
| Document: 0001193125-26-177357-index.html | 0001193125-26-177357 |
| Document: 0001193125-26-177357.txt | 0001193125-26-177357 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | EFFECT | $0.0139 $0.0143 | ▼ −2.88% | ▼ −0.38% | — |
Apr 27, 2026 26w ago | 6-K | $0.0139 $0.0175 | ▲ +25.90% | ▲ +21.12% | — |
Apr 24, 2026 26w ago | 20-F | $0.0139 $0.0175 | ▼ −25.90% | ▼ −21.12% | — |
Apr 1, 2026 29w ago | 6-K | $0.0139 $0.0201 | ▲ +44.60% | ▲ +30.44% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers